Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS

Squarepoint Ops LLC boosted its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 1,679.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 284,567 shares of the company’s stock after buying an additional 268,572 shares during the quarter. Squarepoint Ops LLC owned approximately 0.18% of Xeris Biopharma worth $1,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of XERS. FORA Capital LLC bought a new stake in shares of Xeris Biopharma in the 1st quarter worth approximately $60,000. Tower Research Capital LLC TRC raised its position in Xeris Biopharma by 913.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock worth $81,000 after purchasing an additional 15,678 shares during the period. Modern Wealth Management LLC bought a new stake in Xeris Biopharma in the second quarter worth $83,000. Landscape Capital Management L.L.C. bought a new stake in Xeris Biopharma in the first quarter worth $86,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Xeris Biopharma during the second quarter valued at about $95,000. 42.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

XERS has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Oppenheimer reiterated an “outperform” rating and issued a $18.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Piper Sandler increased their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $7.34 on Friday. The stock has a market cap of $1.22 billion, a P/E ratio of -73.39 and a beta of 0.57. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $3.14 and a fifty-two week high of $10.08. The stock has a 50 day simple moving average of $7.88 and a two-hundred day simple moving average of $6.88.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The company had revenue of $74.38 million during the quarter, compared to the consensus estimate of $74.19 million. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at Xeris Biopharma

In related news, Director John Johnson sold 135,400 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.22, for a total value of $977,588.00. Following the completion of the transaction, the director directly owned 698,083 shares of the company’s stock, valued at $5,040,159.26. This represents a 16.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider John Patrick Shannon, Jr. sold 23,242 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $7.46, for a total transaction of $173,385.32. Following the completion of the sale, the insider owned 2,643,153 shares of the company’s stock, valued at $19,717,921.38. This trade represents a 0.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 206,976 shares of company stock valued at $1,497,495 over the last quarter. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.